(16,146,093) (61,501,349)
Other income (expense):
Interest income 2,022,361 785,016 2,938,459
Warrants issued to related
party guarantors - - (17,505)
Liquidated damages expense:
To related parties - - (1,102,530)
To other parties - - (507,900)
Total other income
(expense) 2,022,361 785,016 1,310,524
Loss before provision for
income taxes (31,740,585) (15,361,077) (60,190,825)
Provision for income taxes 2,400 2,331 8,731
Net loss $(31,742,985) $(15,363,408) $(60,199,556)
Basic and diluted net loss per
share: $(1.14) $(0.63)
Weighted average common shares
outstanding used in the
calculation of basic and
diluted net loss per share 27,932,309 24,247,522
* Includes non-cash stock-based compensation expense.
'/>"/>SOURCE Medivation, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference2.
Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index3.
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results4.
Favrille Reports Fourth Quarter and Year End 2007 Financial Results5.
JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis6.
OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports7.
Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results8.
OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer9.
Escalon(R) Reports Second Quarter Fiscal 2008 Results10.
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 435011.
Eklin Medical Reports Record Revenues for 2007